MedTrace Logo

1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer

NCT02700776 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 417

Last updated 2019-11-07

No results posted yet for this study

Summary

The purpose of this study is find out if a protein level in the blood (called PC Cell Derived Growth Factor or glycoprotein 88 \[GP88\]), combined with standard mammography screening, can help detect breast cancer better than mammography screening alone. Earlier research has shown that a certain glycoprotein 88 (GP88) is higher in women with breast cancer.

In this study, investigators will measure the level of GP88 in the blood of healthy women who are having mammography screening for breast cancer. The investigator plans to correlate the results of the mammogram with the GP-88 level.

Conditions

  • Healthy Volunteers

Interventions

OTHER

Phlebotomy - Blood sampling for GP88 at MM

Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.

PROCEDURE

SOC Tissue biopsy

standard of care tissue biopsy if clinically indicated.

Sponsors & Collaborators

  • A&G Pharmaceutical

    collaborator INDUSTRY

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Katherine Tkaczuk, MD · University of Maryland Greenebaum Cancer Center

Eligibility

Min Age
40 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-02-27
Completion
2017-02-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02700776 on ClinicalTrials.gov